Background: Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging. Both pathogenic and protective mutations illuminate mechanisms of disease and potential interventions. AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation.
Objectives: This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with symptomatic, chronic heart failure.
Methods: ATTR-CM, New York Heart Association functional class II to III subjects (n = 49, mutant or wild-type) were randomized 1:1:1 to AG10 400 mg, AG10 800 mg, or placebo twice daily for 28 days. Safety and tolerability were assessed by clinical and laboratory criteria. AG10 plasma levels were measured. TTR stability was assessed by changes in serum TTR, and 2 established ex vivo assays (fluorescent probe exclusion and Western blot).
Results: AG10 treatment was well-tolerated, achieved target plasma concentrations and demonstrated near-complete stabilization of TTR. TTR stabilization was more complete and less variable at the higher dose with stabilization by fluorescent probe exclusion of 92 ± 10% (mean ± SD) at trough and 96 ± 9% at peak (both p < 10-12 vs. placebo). Average serum TTR increased by 36 ± 21% and 51 ± 38% at 400 and 800 mg, respectively (both p < 0.0001 vs. placebo). Baseline serum TTR in treated subjects was below normal in 80% of mutant and 33% of wild-type subjects. AG10 treatment restored serum TTR to the normal range in all subjects.
Conclusions: AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM. A phase 3 trial is ongoing. (Study of AG10 in Amyloid Cardiomyopathy; NCT03458130).
Keywords: AG10; ATTR-CM; amyloidosis; cardiomyopathy; heart failure; transthyretin.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers.Clin Pharmacol Drug Dev. 2020 Jan;9(1):115-129. doi: 10.1002/cpdd.700. Epub 2019 Jun 6. Clin Pharmacol Drug Dev. 2020. PMID: 31172685 Free PMC article.
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9992-7. doi: 10.1073/pnas.1300761110. Epub 2013 May 28. Proc Natl Acad Sci U S A. 2013. PMID: 23716704 Free PMC article.
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.J Med Chem. 2018 Sep 13;61(17):7862-7876. doi: 10.1021/acs.jmedchem.8b00817. Epub 2018 Aug 22. J Med Chem. 2018. PMID: 30133284 Free PMC article.
Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).Circ Heart Fail. 2017 Jun;10(6):e003815. doi: 10.1161/CIRCHEARTFAILURE.116.003815. Circ Heart Fail. 2017. PMID: 28611125 Review.
Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):1036-43. doi: 10.1136/jnnp-2014-308724. Epub 2015 Jan 20. J Neurol Neurosurg Psychiatry. 2015. PMID: 25604431 Review.
Cited by 12 articles
Molecular dynamics simulation study of AG10 and tafamidis binding to the Val122Ile transthyretin variant.Biochem Biophys Rep. 2020 Jan 17;21:100721. doi: 10.1016/j.bbrep.2019.100721. eCollection 2020 Mar. Biochem Biophys Rep. 2020. PMID: 32055713 Free PMC article.
Recent advances in the treatment of chronic heart failure.F1000Res. 2019 Dec 20;8:F1000 Faculty Rev-2134. doi: 10.12688/f1000research.20447.1. eCollection 2019. F1000Res. 2019. PMID: 31942237 Free PMC article. Review.
Amyloid and the Heart.Curr Cardiol Rep. 2019 Dec 3;21(12):164. doi: 10.1007/s11886-019-1230-9. Curr Cardiol Rep. 2019. PMID: 31792619 Review.
Amyloidosis in Heart Failure.Curr Heart Fail Rep. 2019 Dec;16(6):285-303. doi: 10.1007/s11897-019-00446-x. Curr Heart Fail Rep. 2019. PMID: 31782077 Review.
Disease-modifying therapy for proteinopathies: Can the exception become the rule?Prog Mol Biol Transl Sci. 2019;168:277-287. doi: 10.1016/bs.pmbts.2019.07.010. Epub 2019 Aug 7. Prog Mol Biol Transl Sci. 2019. PMID: 31699321